Alnylam Pharmaceuticals, Inc. made a presentation at the European Society of Cardiology 2025 Congress, highlighting advancements in using RNAi therapeutics to treat cardiovascular disease.
The company’s stock price has reached a 52-week high of $457.92 USD and a 52-week low of $205.87 USD. As of the current market, the stock price is $456.87 USD.
Key Financial Metrics
- 52-week high: $457.92 USD
- 52-week low: $205.87 USD
- Current stock price: $456.87 USD
The company’s price-to-earnings ratio is -182.642 and the price-to-book ratio is 235.503. These metrics indicate a complex valuation landscape for the company.